Showing 321 - 340 results of 113,828 for search '(( 12 we decrease ) OR ( 5 ((((wt decrease) OR (mean decrease))) OR (a decrease)) ))', query time: 0.95s Refine Results
  1. 321
  2. 322
  3. 323
  4. 324
  5. 325
  6. 326

    Cdk5 siRNA knockdown decreased Cdk5 activity, diminished WT1 expression and viable cell numbers, and increased cleaved caspase 3 level. by Ya-Li Zheng (454837)

    Published 2016
    “…Western blotting analysis showed a decline of WT1 expression in Cdk5 siRNA podocytes (upper panel, lane 2). …”
  7. 327
  8. 328
  9. 329
  10. 330
  11. 331
  12. 332
  13. 333

    Knockdown of AR expression decreases the efficiency of KSHV infection in endothelial cells. by Xing Wang (154377)

    Published 2017
    “…(g, h) Knockdown of AR and EphA2 expression decreases nuclear LANA expression in SLK cells, as determined by an immunofluorescence assay and quantitative analysis by Image J software. …”
  14. 334
  15. 335
  16. 336

    Decreasing ShcA expression enhances TGF-β-induced Smad signaling. by Baby Periyanayaki Muthusamy (838234)

    Published 2015
    “…The error bars show standard error of the mean, based on three independent experiments. Supplemental data are shown in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1002325#pbio.1002325.s006" target="_blank">S5 Fig</a> and <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1002325#pbio.1002325.s001" target="_blank">S1 Data</a>.…”
  17. 337
  18. 338

    The Immunologic Effects of Mesalamine in Treated HIV-Infected Individuals with Incomplete CD4+ T Cell Recovery: A Randomized Crossover Trial by Ma Somsouk (283498)

    Published 2014
    “…The effect of mesalamine in HIV-infected individuals, who exhibit abnormal mucosal immune activation and microbial translocation (MT), has not been established in a placebo-controlled trial. We randomized 33 HIV-infected subjects with CD4 counts <350 cells/mm<sup>3</sup> and plasma HIV RNA levels <40 copies/ml on antiretroviral therapy (ART) to add mesalamine vs. placebo to their existing regimen for 12 weeks followed by a 12 week crossover to the other arm. …”
  19. 339
  20. 340